Home › Employers › Spogen Biotech Inc
Spogen Biotech Inc: H-1B salaries and sponsorship
Spogen Biotech Inc filed 3 labor condition applications for H-1B and related visas in fiscal years 2023–2026; certified: 3. Median offered salary: $90,000.
Does Spogen Biotech Inc sponsor H-1B visas?
Spogen Biotech Inc filed 3 labor condition applications in fiscal years 2023–2026, the latest submitted on Dec 18, 2025. An LCA is the first step of an H-1B petition, so the employer has sponsored or prepared to sponsor H-1B workers; it does not guarantee sponsorship for any particular job. Check the employer's own job listings.
Salaries by job title
| Job title | LCAs | Median salary |
|---|---|---|
| Principal Manufacturing Scientist | 1 | $90,000 |
| Research Scientist I “ Formulation | 1 | $80,500 |
| Research Scientist II - Formulation | 1 | $100,131 |
Applications by fiscal year
| Fiscal year | LCAs | Median salary |
|---|---|---|
| FY2023 | 1 | $90,000 |
| FY2025 | 1 | $80,500 |
| FY2026 | 1 | $100,131 |
Prevailing wage levels
The Department of Labor sets four prevailing wage levels for each occupation and area, from Level I (entry) to Level IV (fully competent). The employer picks the level that matches the job's requirements.
Where the jobs are
Occupations
Latest applications
| Job title | Base salary | Location | Submitted | Start date | Status |
|---|---|---|---|---|---|
| Research Scientist II - Formulation | $100,131–$105,000 Level III | St. Louis, MO | Dec 18, 2025 | Jan 1, 2026 | Certified |
| Research Scientist I “ Formulation | $80,500 Level I | St. Louis, MO | May 12, 2025 | Oct 1, 2025 | Certified |
| Principal Manufacturing Scientist | $90,000–$115,000 Level III | St. Louis, MO | Mar 14, 2023 | Apr 3, 2023 | Certified |
Salaries are the lower end of the wage offered on each application, converted to a yearly amount; statistics use certified full-time applications only. An LCA is not a visa approval and one LCA can cover several positions. Source: U.S. Department of Labor, OFLC LCA Disclosure Data, fiscal years 2023–2026 (latest decision Jun 30, 2026).